Tasocitinib (CP-690,550) has been found to reduce the signs and symptoms of rheumatoid arthritis considerably, as well as significantly improving physical function according to a Phase 3 clinical trial, ORAL Solo (1045), says Pfizer. Tasocitinib, used as a monotherapy - on its own - is an oral JAK (Janus kinase) inhibitor. The experimental pill reduced inflammation and pain symptoms for 71% of trial patients; inflammation was reduced by at least 20% after a six-month period...
More...
More...